| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CNR2 |
| Uniprot No | P34972 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-360aa |
| 氨基酸序列 | MEECWVTEIANGSKDGLDSNPMKDYMILSGPQKTAVAVLCTLLGLLSALE NVAVLYLILSSHQLRRKPSYLFIGSLAGADFLASVVFACSFVNFHVFHGV DSKAVFLLKIGSVTMTFTASVGSLLLTAIDRYLCLRYPPSYKALLTRGRA LVTLGIMWVLSALVSYLPLMGWTCCPRPCSELFPLIPNDYLLSWLLFIAF LFSGIIYTYGHVLWKAHQHVASLSGHQDRQVPGMARMRLDVRLAKTLGLV LAVLLICWFPVLALMAHSLATTLSDQVKKAFAFCSMLCLINSMVNPVIYA LRSGEIRSSAHHCLAHWKKCVRGLGSEAKEEAPRSSVTETEADGKITPWP DSRDLDLSDC |
| 预测分子量 | 66 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CNR2(大麻素受体2型)重组蛋白的3篇参考文献示例(文献信息为模拟，供参考)：
---
1. **"Structural insights into the human cannabinoid receptor CB2 activation by lipid agonists"**
*作者：Zhang X. et al. (2021)*
**摘要**：通过冷冻电镜解析人源CNR2重组蛋白与内源性脂质配体结合的高分辨率结构，揭示了其激活机制及信号传导途径，为靶向CNR2的药物设计提供结构基础。
2. **"Expression and functional characterization of recombinant CB2 in mammalian cells for ligand screening"**
*作者：Mackie K. et al. (2005)*
**摘要**：报道了在HEK293细胞中高效表达CNR2重组蛋白的方法，并通过配体结合实验验证其功能，证明其在炎症相关信号通路中的调控作用。
3. **"CB2 receptor signaling in neuroinflammation: Insights from a recombinant protein model"**
*作者：Stella N. et al. (2016)*
**摘要**：利用重组CNR2蛋白模型研究其在神经炎症中的作用，发现其通过抑制小胶质细胞激活减轻神经退行性疾病中的炎症反应。
---
注：以上文献为示例，实际文献需通过PubMed、Web of Science等数据库检索确认。建议以“CB2 receptor”“recombinant protein”“cannabinoid receptor type 2”为关键词进行精准查询。
The CNR2 recombinant protein is derived from the human cannabinoid receptor type 2 (CB2), a G protein-coupled receptor (GPCR) primarily expressed in immune cells and peripheral tissues. CB2 plays a key role in modulating immune responses, inflammation, and pain signaling by interacting with endogenous cannabinoids, plant-derived cannabinoids (e.g., THC), and synthetic ligands. Unlike its closely related counterpart, cannabinoid receptor type 1 (CB1), which is predominantly found in the central nervous system, CB2 has limited expression in the brain, making it a promising therapeutic target for inflammatory and autoimmune diseases with reduced psychoactive side effects.
Recombinant CNR2 proteins are engineered using heterologous expression systems, such as mammalian cells, insect cells, or Escherichia coli, to produce purified, functional receptors for research and drug development. These proteins retain structural and functional integrity, enabling studies on ligand binding, receptor activation, and downstream signaling pathways (e.g., inhibition of adenylate cyclase, MAPK activation). Researchers utilize CNR2 recombinant proteins to screen potential therapeutics for conditions like rheumatoid arthritis, neuropathic pain, and neurodegenerative disorders. However, challenges remain in stabilizing the protein’s conformation and improving solubility due to GPCR complexity. Recent advances in cryo-EM and computational modeling have enhanced structural insights, aiding the design of selective CB2 agonists/antagonists. Overall, CNR2 recombinant proteins serve as critical tools for unraveling cannabinoid biology and advancing targeted therapies.
×
